title: Expression of monocyte chemotactic protein-1 in human endometrial cancer cells and the effect of treatment with tamoxifen or buserelin.
abstract: Monocyte chemotactic protein-1 (MCP-1) is an important determinant of macrophage infiltration in tumours. This study investigated the effect of tamoxifen and the gonadotrophin-releasing hormone agonist buserelin on MCP-1 in the human endometrial cancer cell line EFE-184. Reverse transcription polymerase chain reaction and Western blot analysis were used to determine MCP-1 mRNA and protein expression, respectively. Immunoreactive MCP-1 in the cell culture media was quantified by enzyme-linked immunosorbent assay. Tamoxifen inhibited MCP-1 mRNA and protein expression in endometrial cancer cells and inhibited MCP-1 secretion in a time- and dose-dependent manner at concentrations of 10(-7) to 10(-5) M. Buserelin had no significant effect on MCP-1 mRNA and protein expression. These results suggest that tamoxifen directly inhibits the expression of MCP-1 in this cell line by blocking the MCP-1 signalling pathways. These findings may contribute to the understanding of the mechanisms underlying the different effects of tamoxifen and gonadotrophin-releasing hormone agonists in the treatment of endometrial cancer.
authors.affiliation: Department of Gynaecology, Second Affiliated Hospital, Medical College, Zhejiang University, Hangzhou, China.
authors.forename: L
authors.initials: L
authors.lastname: Wang
authors.forename: W
authors.initials: W
authors.lastname: Zheng
authors.forename: S
authors.initials: S
authors.lastname: Zhang
authors.forename: X
authors.initials: X
authors.lastname: Chen
authors.forename: D
authors.initials: D
authors.lastname: Hornung
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D002064:Buserelin / Q000627:therapeutic use*; D045744:Cell Line, Tumor; D018932:Chemokine CCL2 / Q000235:genetics / Q000378:metabolism*; D016889:Endometrial Neoplasms / Q000188:drug therapy* / Q000378:metabolism*; D005260:Female; D006801:Humans; D020133:Reverse Transcriptase Polymerase Chain Reaction; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use; D013629:Tamoxifen / Q000627:therapeutic use*
chemical_list: D018931:Antineoplastic Agents, Hormonal; C111835:CCL2 protein, human; D018932:Chemokine CCL2; D020845:Selective Estrogen Receptor Modulators; D013629:Tamoxifen; D002064:Buserelin